Absci Corporation
NASDAQ:ABSIBiotechnology
+$0.08 today
- Market cap
- $1.41B
- Beta
- 2.46
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$0.77
Volume 5.66M
Average 5.10M
Returns on capital
Absci Corporation management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-60.8%
avg -36.0%
ROIC
-63.6%
avg -40.7%
ROA
-53.3%
avg -37.0%
Analysis
ROA is currently the strongest return metric at -53.3% versus its period average of -37.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sean McClain | Founder, Chief Executive Officer, President & Director | USD 1.08M | 36 | 8.55M | 5.49% |
Zachariah Jonasson | Chief Business Officer & Chief Financial Officer | USD 816.51K | 53 | 484.92K | 0.31% |
Christine Lemke | Senior Vice President of Portfolio & Growth Strategy | — | — | — | — |
Moetaz Albizem | Senior Vice President of Clinical Operations | — | — | — | — |
Shelby Walker | Chief Legal Officer | — | 51 | — | — |
Ransi Somaratne FACC | Chief Medical Officer | — | 60 | — | — |
Alexander Khan | CVP of Finance & Head of Investor Relations | — | — | — | — |
Todd Bedrick | Senior Vice President & Chief Accounting Officer | — | — | 199.13K | 0.13% |
Jeanne Schreuder SPHR | Senior Vice President of People & Experience | — | — | — | — |
Wen Sha | Chief of Staff | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 29, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$933,174.38
Sells
2
$132,328.43
Net Transaction Value
+$800,845.95
Net buying
Most Active
Pangalos Menelas N
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 30, 26Jun 30, 2026 | Szela Mary T Direct | Buy | $148.9K$148,866.00 |
| May 13, 26May 13, 2026 | Pangalos Menelas N Direct | Buy | $200.7K$200,748.08 |
| Mar 12, 26Mar 12, 2026 | Busch Andreas Direct | Buy | $229K$229,000.00 |
| Feb 27, 26Feb 27, 2026 | Pangalos Menelas N Direct | Buy | $205.8K$205,760.30 |
| Feb 2, 26Feb 2, 2026 | McClain Sean Direct | Sell | $80K$80,015.39 |
| Feb 2, 26Feb 2, 2026 | Jonasson Zachariah Direct | Sell | $52.3K$52,313.04 |
| Dec 5, 25Dec 5, 2025 | VAN HOUTEN FRANS Direct | Buy | $148.8K$148,800.00 |
Summary
Insiders reported 5 buys worth $933,174.38 and 2 sells worth $132,328.43 over the last 12 months. That adds up to net buying of $800,845.95. Pangalos Menelas N was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -21.3% | +80.6% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -21.3% over three years. Forward estimates point to Revenue at +80.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Absci Corporation compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ABSI's management, answered from reported figures.
Who manages ABSI?
Absci Corporation (ABSI) lists 10 active executives. The top listed executive is Christine Lemke, Senior Vice President of Portfolio & Growth Strategy.
Are ABSI insiders buying or selling?
Recent insider activity shows net buying of $177.95M.
Continue the stock analysis
Jump to another research area for this company.